Bruton's tyrosine kinase (BTK) is an essential component of multiple signaling pathways that
regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising …

Bruton's tyrosine kinase (BTK) inhibitor is a promising novel agent that has potential
efficiency in B-cell malignancies. It took approximately 20 years from target discovery to new …

Herein, we present the long-term follow-up of the randomized E1912 trial comparing the
long-term efficacy of ibrutinib–rituximab (IR) therapy to fludarabine, cyclophosphamide, and …

The cytoplasmic protein-tyrosine kinase BTK plays an essential role for differentiation and
survival of B-lineage cells and, hence, represents a suitable drug target. The number of BTK …

Zanubrutinib is a potent and highly selective inhibitor of Bruton tyrosine kinase (BTK). In this
first-in-human, open-label, multicenter, phase 1 study, patients in part 1 (3+ 3 dose …

Background Both single-agent ibrutinib and chlorambucil plus obinutuzumab have shown
superior efficacy to chlorambucil monotherapy and are standard first-line treatments in …

Background Deletion of chromosome 17p (del [17p]) in patients with chronic lymphocytic
leukaemia confers very poor prognosis when treated with standard chemo-immunotherapy …

B cell receptor (BCR) signalling is crucial for normal B cell development and adaptive
immunity. BCR signalling also supports the survival and growth of malignant B cells in …

Despite promising results with targeted drugs, chemoimmunotherapy with fludarabine,
cyclophosphamide (FC), and rituximab (R) remains the standard therapy for fit patients with …

Chronic lymphocytic leukaemia (CLL), the most frequent type of leukaemia in adults, is a
lymphoproliferative disorder that is characterized by the expansion of monoclonal, mature …